Therapeutics M&A Transactions

United Therapeutics acquires Thymmune Therapeutics, enhancing its regenerative medicine and cell therapy capabilities with a $300 million deal including earn-outs.

Ipsen to acquire Memo Therapeutics AG for up to €700M, gaining a Phase II antibody for BKPyV. Kurma Partners and Eurazeo Group are key stakeholders in this significant biotech deal.

Ipsen secures Kartos Therapeutics' navtemadlin in a deal up to $1.75B, enhancing its hemato-oncology pipeline with a promising myelofibrosis treatment.

Ipsen secures navtemadlin, a novel myelofibrosis therapy, in a deal valued up to $1.3 billion, targeting unmet needs in rare blood cancers.

Thalia Therapeutics

UK biotech Thalia Therapeutics secures €3.1 million and acquires Sanmirna Therapeutics, enhancing its RNA-based oncology and cardiovascular drug development.

Boundless Bio

Boundless Bio and Serapha Bio unite in a merger, raising $230 million to pioneer a gene editing therapy for Alpha-1 Antitrypsin Deficiency.

AbbVie nears $10.9 billion deal for Apogee Therapeutics, boosting its inflammatory disease pipeline with a long-acting drug candidate. Industry M&A heats up.

Biogen strengthens its immunology pipeline by acquiring RayThera for up to $1 billion, gaining access to promising small-molecule therapies for immune-mediated diseases.